期刊文献+

胰腺癌精确放疗的疗效及预后因素 被引量:5

Effectiveness and Prognostic Factors of Precise Radiotherapy for Pancreatic Cancer
下载PDF
导出
摘要 目的 分析胰腺癌的精确放疗疗效及预后因素.方法 2003年1月至2012年6月间接受精确放疗的胰腺癌患者102例,其中根治性放疗54例,辅助性放疗48例;三维适形放疗平均16例,调强放疗86例;中位放疗剂量50 Gy,1.8~2.2 Gy/次.13例同步卡培他滨化疗.结果 所有患者总生存时间(overall survival,OS)为(14±1.2)个月,无进展生存时间(progress-free survival,PFS)为(9±1.1)个月.1、2、5年生存率分别为63.3%、22.6%、10%.毒性反应包括3级消化道毒性5例,未发生3、4级血液学和4级消化道毒性反应.单因素分析结果表明,治疗前体重下降>5 kg(P <0.0001)、T分期(P =0.011)、TNM分期(P =0.007)、是否行肿瘤切除术(P =0.001)是影响OS的预后因素,同时也是PFS的预后因素.多因素分析结果表明,肿瘤切除术是OS的预后因素(x2=5.416,P=0.020).结论 在胰腺癌的根治性放疗和辅助性放疗中,三维适形放疗和调强放疗都可以较好地耐受,3、4级毒性反应较少,为放化疗同步及肿瘤放疗剂量的提升提供了可行性;手术切除提高了OS. Objective To analyze the effectiveness and prognostic factors of precise radiotherapy for pan- creatic cancer. Methods Totally 102 patients with pancreatic cancer received precise radiotherapy in our hospi- tal between January 2003 and June 2012, among whom 54 received radical radiotherapy and 48 underwent adju- vant radiotherapy. Three-dimensional conformal radiotherapy (3D-CRT) was performed in 16 cases and intensity- modulated radiotherapy (IMRT) in 86 cases, with a median radiotherapy dose of 50 Gy ( 1.8 ~ 2. 2 Gy/frac- tion). Concurrent capecitabine chemotherapy was carried out in 13 cases. Results The average overall survival time (OS) and the average time to progress-free survival (PFS) was ( 14 _+ 1.2) months and (9 -+ 1.1 ) months, respectively. The 1-, 2-, and 5-year survival rates were 63.3% , 22.6% , and 10% , respectively. Grade 3 gas- trointestinal toxicity occurred in 5 cases. No grade 3 or 4 hematologic toxicity and grade 4 gastrointestinal toxicity was observed. Univariate analysis showed that weight loss of 〉 5 kg before treatment ( P 〈 0. 0001 ), T stage (P =0. 011 ), TNM stage (P =0. 007), and surgical excision (P =0. 001 ) were significantly associated with OS and PFS. Multivariate analysis showed that surgical excision was a prognostic factor for OS (X2 = 5. 416, P = 0. 020). Conclusions The precise radiotherapy including 3D-CRT and IMRT can be tolerated with fewer grade 3 and 4 toxicities in pancreatic cancer patients after radical radiotherapy and adjuvant radiotherapy, thus make it feasible for the concurrent chemotherapy and the increase of radiotherapy dose. Surgical excision can improve the OS of pancreatic cancer patients.
出处 《协和医学杂志》 2013年第4期371-376,共6页 Medical Journal of Peking Union Medical College Hospital
关键词 胰腺癌 三维适形放疗 调强放疗 预后 pancreatic cancer three-dimensional conformal radiotherapy intensity modulated radiation therapy prognosis
  • 相关文献

参考文献17

  • 1Jacobs NL, Que FG, Miller RC, et al. Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer[J].J Gastroinstestinal Cancer, 2009, 40: 46- 50.
  • 2Spinelli GP, Zullo A, Romiti A, et al. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature[J].JOP, 2006, 7: 486-491.
  • 3Keleg S, BUchler P, Ludwig R, et al. Invasion and metasta?sis in pancreatic cancer[J]. Mol Can, 2003, 2: 14.
  • 4Garcea G, Dennison AR, Pattenden CJ, et al. Survival fol?lowing curative resection for pancreatic ductal adenocarcino?ma. A systematic review of the literature[J].JOP, 2008, 9: 99-132.
  • 5Royal RE, Wolff RA, Crane CH. Cancer of the pancreas[M] I IDe Vita VTJ, Lawrence TS, Rosenberg SA, eds. Principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1086-1123.
  • 6Abbott DE, Baker MS, Talamonti MS. Neoadjuvanttherapy for pancreatic cancer: acurrent review[J].J Surg Oncol, 2010, 101: 315-320.
  • 7AbelsonJA, MurphyJD, MinnA Y, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma[J]. UROBP, 2012, 82: e595-e601.
  • 8Smeenk HG, van Eijick CHJ, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long?term results of EORTC trial 40891[J]. Ann Surg, 2007, 246: 734-740.
  • 9NeoptolemosJP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N EnglJ Med, 2004, 350: 1200-1210.
  • 10Stessin AM, MeyerJE, Sherr DL, et al. Neoadjuvant radia?tion is associated with improved survival in patients with re- sectable pancreatic cancer: an analysis of data from the sur?veillance, epidemiology, and end results (SEER) registry[J]. UROBP, 2008, 72: 1128-1133.

同被引文献55

  • 1谷琥之,殷蔚伯.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:837-854.
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics [ J]. CA Cancer J Clin, 2007, 57: 43-66.
  • 3Palma DA, Verbakel WF, Otto K, et al. New developments in arc radiation therapy: a review [ J]. Cancer Treat Rev, 2010, 36: 393-399.
  • 4Brown MW, Ning H, Arora B, et al. Adosimetric analysis of dose escalation using two intensity-modulated radiation thera- py techniques in locally advanced pancreatic carcinoma [J]. Int J Radiat Oncol Biol Phys, 2006, 65 : 274-283.
  • 5Yovino S, Poppe M, Jabbour S, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers [ Jl. Int J Radi- at Oncol Biol Phys, 2011,79: 158-162.
  • 6Kjaer-Kristoffersen F, Ohlhues L, Medin J, et al. RapidArc volumetric modulated therapy planning for prostate cancer pa- tients [J]. Acta Oncol, 2009, 48: 227-232.
  • 7Vanetti E, Clivio A, Nicolini G, et al. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-phar- ynx and larynx: a treatment planning comparison with fixed field IMRT [J]. Radiother Oncol, 2009, 92: 111-117.
  • 8Oliver M, Ansbacher W, Beckham WA. Comparing planning time, delivery time and plan quality for IMRT, RapidArc and Tomotherapy [J]. J Appl Clin Med Phys, 2009, 10: 3068.
  • 9Hoogeman MS, Nuyttens J J, Levendag PC, et al. Time de- pendence of intrafraction patient motion assed by repeat stere- oscopic imaging [ J ]. Int J Radiat Oncol Biol Phys, 2008, 70: 609-618.
  • 10Nahavizadeh H, Simeonova AO, Waller JG, et al. Volumetric-modula- ted arc radiotherapy for pancreatic malignancies: Dosimetric compari- son with sliding-window intensity-modulated radiotherapy and 3-di- mensional conformal radiotherapy[J]. Med Dosim, 2014,39 ( 3 ) : 256- 260.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部